FDA gives Genentech’s Gazyva Priority Review for primary membranous nephropathy
FDA Priority Review puts Genentech’s Gazyva on a November decision path in primary membranous nephropathy after the Phase III MAJESTY win.
Pharma & Biotech
Pharma & Biotech
Why Aurinia’s new Lupkynis trial could change the lupus nephritis treatment sequence
Discover how Aurinia’s PRESERVE study could reshape lupus nephritis care by combining Lupkynis with three major biologic therapies.
Pharma & Biotech
AbbVie’s Venclexta update puts long-term CLL treatment-free survival back in focus
Find out how AbbVie’s nine-year venetoclax CLL data could reshape fixed-duration treatment decisions and long-term leukemia care.
Pharma & Biotech
FDA accepts Genentech’s Gazyva application for SLE, what it means for lupus treatment
FDA accepts Genentech’s Gazyva filing for systemic lupus erythematosus. Read what the ALLEGORY data could mean for lupus treatment in 2026.
Pharma & Biotech
Gazyva’s ALLEGORY data: what the SRI-4 and DORIS remission outcomes mean for lupus care
Genentech's obinutuzumab met all ALLEGORY phase III endpoints in SLE. What the remission and flare data mean for lupus treatment strategy.
Pharma & Biotech
Genentech advances Gazyva toward first approval in primary membranous nephropathy after Phase III win
Discover how Genentech’s Gazyva Phase III data could reshape treatment goals in membranous nephropathy and what regulators and clinicians will watch next.